首页> 外文期刊>Advanced Functional Materials >Engineering of Lipid Nanoparticles by the Multifunationalization of the Surface with Ami no Acid Derivatives for the Neutralization of a Target Toxic Peptide
【24h】

Engineering of Lipid Nanoparticles by the Multifunationalization of the Surface with Ami no Acid Derivatives for the Neutralization of a Target Toxic Peptide

机译:用AMI NO酸性衍生物的中和衍生物的脂质纳米粒子的脂质纳米粒子的工程

获取原文
获取原文并翻译 | 示例
           

摘要

Protein affinity reagents (e.g., antibodies) are often used for basic research, diagnostics, separations, and disease therapy. Although a lot of "synthetic" protein affinity reagents have been developed as a cost-effective alternative to antibodies, their low biocompatibility is a considerable problem for clinical application. Lipid nanoparticles (LNP) represent a highly biocompatible drug delivery agent. However, little has been reported that LNP itself works as a protein affinity reagent in living animals. Here, LNP is engineered for binding to and neutralizing a target toxic peptide in living animals by multifunctionalization with amino acid derivatives. Multifunctionalized LNP (MF-LNP) is prepared using amino acid derivative-conjugated lipids. Optimized MF-LNP exhibits nanomolar affinity to the target toxic peptide and inhibits toxic peptide-dependent hemolysis and cytotoxicity. In addition, MF-LNP captures and neutralizes the toxic peptide after intravenous injection in the bloodstream; in addition, MF-LNP does not release the toxic peptide in the accumulated organ. These results reveal the potential of using LNP as a highly biocompatible protein affinity reagent such as an antidote.
机译:蛋白质亲和试剂(例如,抗体)通常用于基础研究,诊断,分离和疾病治疗。虽然已经开发了许多“合成”蛋白亲和力试剂作为对抗体的经济有效替代方案,但它们的低生物相容性是临床应用的相当大问题。脂质纳米颗粒(LNP)代表高度生物相容性的药物递送剂。然而,很少据报道,LNP本身在活性动物中作为蛋白质亲和力试剂。这里,通过用氨基酸衍生物的多官能化设计,LNP被设计用于结合并中和活体动物中的靶毒性肽。使用氨基酸衍生物 - 缀合的脂质制备多官化LNP(MF-LNP)。优化的MF-LNP表现出对靶有毒肽的纳米摩尔亲和力,并抑制有毒的肽依赖性溶血和细胞毒性。此外,MF-LNP在血液中静脉注射后捕获和中和毒性肽;此外,MF-LNP不会在累积器官中释放毒性肽。这些结果揭示了使用LNP作为高度生物相容性蛋白质亲和试剂如解毒剂的潜力。

著录项

  • 来源
    《Advanced Functional Materials》 |2021年第3期|2005641.1-2005641.10|共10页
  • 作者单位

    Univ Shizuoka Sch Pharmaceut Sci Dept Med Biochem Suruga Ku 52-1 Yada Shizuoka Shizuoka 4228526 Japan;

    Univ Shizuoka Sch Pharmaceut Sci Dept Med Biochem Suruga Ku 52-1 Yada Shizuoka Shizuoka 4228526 Japan;

    Univ Shizuoka Sch Pharmaceut Sci Suruga Ku 52-1 Yada Shizuoka Shizuoka 4228526 Japan;

    Univ Shizuoka Sch Pharmaceut Sci Dept Med Biochem Suruga Ku 52-1 Yada Shizuoka Shizuoka 4228526 Japan;

    Univ Shizuoka Sch Pharmaceut Sci Dept Med Biochem Suruga Ku 52-1 Yada Shizuoka Shizuoka 4228526 Japan;

    Univ Shizuoka Sch Pharmaceut Sci Dept Med Biochem Suruga Ku 52-1 Yada Shizuoka Shizuoka 4228526 Japan;

    Univ Shizuoka Sch Pharmaceut Sci Suruga Ku 52-1 Yada Shizuoka Shizuoka 4228526 Japan;

    Univ Shizuoka Sch Pharmaceut Sci Dept Med Biochem Suruga Ku 52-1 Yada Shizuoka Shizuoka 4228526 Japan;

    Univ Shizuoka Sch Pharmaceut Sci Dept Med Biochem Suruga Ku 52-1 Yada Shizuoka Shizuoka 4228526 Japan;

    Univ Shizuoka Sch Pharmaceut Sci Dept Med Biochem Suruga Ku 52-1 Yada Shizuoka Shizuoka 4228526 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    amino acid; antibody; molecular recognition; nanoparticle; toxin;

    机译:氨基酸;抗体;分子识别;纳米粒子;毒素;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号